Epigenetics involved in multiple normal cellular processes. Previous research have revealed the role of hepatitis C virus infection in accelerating methylation process and affecting response to treatment in chronic hepatitis patients. This work aimed to elucidate the role of promoter methylation (PM) in response to antiviral therapy, and its contribution to the development of fibrosis through hepatocarcinogenesis-related genes. A total of 159 chronic hepatitis Egyptian patients versus 100 healthy control group were included. The methylation profile of a panel 9 genes (SFRP1, p14, p73, APC, DAPK, RASSF1A, LINE1, O6MGMT, and p16) was detected in patients’ plasma using methylation-specific polymerase chain reaction (MSP). Clinical and laboratory findings were gathered for patients with combined pegylated interferon and ribavirin antiviral therapy. Regarding the patients’ response to antiviral therapy, the percentage of non-responders for APC, O6MGMT, RASSF1A, SFRP1, and p16 methylated genes were significantly higher versus responders (P<0.05). Of the 159 included patients, the most frequent methylated genes were SFRP1 (102/159), followed by p16 (100/159), RASSF1A (98/159), then LINE1 (81/159), P73 (81/159), APC (78/159), DAPK (66/159), O6MGMT (66/159), and p14 (54/159). A total of 67/98 (68.4%) cases of RASSF1A methylated gene (P=0.0.024), and 62/100 (62%) cases of P16 methylated gene (P=0.03) were associated with mild-degree fibrosis. To recapitulate, the PM of SFRP1, APC, RASSF1A, O6MGMT, and p16 genes increases in chronic hepatitis C patients, and can affect patients’ response to antiviral therapy. The RASSF1A and P16 genes might have a role in the distinction between mild and marked fibrosis.
Citations
Citations to this article as recorded by
The COVID-19 legacy: consequences for the human DNA methylome and therapeutic perspectives Carlo Gaetano, Sandra Atlante, Michela Gottardi Zamperla, Veronica Barbi, Davide Gentilini, Barbara Illi, Marco Malavolta, Fabio Martelli, Antonella Farsetti GeroScience.2024; 47(1): 483. CrossRef
Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia Nikola Kokanov, Snezana Jovanovic-Cupic, Marina Siljic, Valentina Cirkovic, Nina Petrovic, Bojana Kozik, Milena Krajnovic Archives of Biological Sciences.2023; 75(3): 251. CrossRef
RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin Nikola Kokanov, Milena Krajnovic, Snezana Cupic-Jovanovic, Bojana Kozik, Nina Petrovic, Ana Bozovic, Vesna Mandusic Archives of Biological Sciences.2022; 74(1): 57. CrossRef
Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea Jae Seung Lee, Hong Jun Choi, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(9): 2479. CrossRef
A longitudinal sampling study of transcriptomic and epigenetic profiles in patients with thrombocytopenia syndrome Yafen Wang, Shaoqing Han, Ruoxi Ran, Anling Li, Huanyu Liu, Mingjun Liu, Yongwei Duan, Xiong Zhang, Zhigang Zhao, Shihui Song, Xiaocheng Weng, Song-Mei Liu, Xiang Zhou Nature Communications.2021;[Epub] CrossRef
Combination therapy of pegylated interferon α and ribavirin has been associated with various adverse effects, but sudden-onset hearing loss is uncommon. We report a 60-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon α and ribavirin for chronic hepatitis C. This patient had been diagnosed with chronic hepatitis C (genotype Ib) and early-stage liver cirrhosis 3 years previously, and had been treated with conventional interferon-α and ribavirin for 12 months. However, 6 months from the end of the treatment course the patient relapsed and received combination retreatment with pegylated interferon α-2b and ribavirin. He developed sudden-onset right-side hearing loss and tinnitus 42 weeks after the start of this retreatment. Pure-tone audiometry revealed a right-side hearing loss of 60~90dB. The patient consequently immediately discontinued the pegylated interferon therapy and was given prednisone 60 mg/day for 10 days, after which the hearing loss had almost completely recovered. (Korean J Hepatol 2009;15:370-374)
Citations
Citations to this article as recorded by
A Narrative Review of Pharmacologic Treatments for COVID‐19: Safety Considerations and Ototoxicity Christine Little, Maura K. Cosetti The Laryngoscope.2021; 131(7): 1626. CrossRef
Cochlear Changes Caused by Peginterferon α-2b Reham F. Zittoon, Yasser T. Madian, Diaa Eldeen M. Alhennawi, Hany S. Nadeem Journal of Interferon & Cytokine Research.2018; 38(7): 311. CrossRef
Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy Savita Jain, Vandana Midha, Ajit Sood Indian Journal of Gastroenterology.2011; 30(5): 239. CrossRef
First
Prev
